JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
80 hedge funds and large institutions have $153M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
80
Holders Change
-4
Holders Change %
-4.76%
% of All Funds
1.73%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
9
Increased
25
Reduced
30
Closed
13
Calls
$171K
Puts
–
Net Calls
+$171K
Net Calls Change
+$153K
Top Buyers
Top Sellers
| 1 |
JPMorgan Chase & Co
New York
|
$1.74M |
| 2 |
Two Sigma Investments
New York
|
$1.21M |
| 3 |
Renaissance Technologies
New York
|
$79K |
| 4 |
Millennium Management
New York
|
$0 |
| 5 |
Morgan Stanley
New York
|
$101K |
